Senior Associate, Patent Attorney


Andrew has worked in the IP sector since 2006, including over 10 years in-house at a leading global biopharmaceutical firm prior to joining Mewburn Ellis. His previous experience has included supporting all IP aspects of preclinical & clinical stage pharma projects, and involved taking a multi-billion USD/year drug project from first patent draft through to worldwide launch. He has worked extensively with third party collaborators, universities, research institutions, and other pharma companies.

In addition to his expertise in the fundamentals of drafting, worldwide prosecution and freedom-to-operate analysis, Andrew possesses the ability to deliver pragmatic business-focused IP advice in line with commercial, practical and other real-world considerations. Andrew is particularly knowledgeable about SPCs and Patent Term Extensions worldwide and understands the broader commercial picture when pharmaceutical regulatory protection periods are taken into account. He has extensive experience with IP agreements (collaborations, licences, deal structures, etc.) asset evaluations, due diligences, deals/transactions, pharmaceutical patent listings and life-cycle management strategies.

Andrew has managed and advised on significant contentious Freedom to Operate issues, taken a lead role in IP dispute resolutions and has experience of managing multi-jurisdictional IP litigation-related activities. Andrew is adept at delivering well-received written and oral briefings to the most senior executives of an organisation – distilling complex issues into a digestible format with a focus on the big picture issues that matter.

Areas of

  • Pharmaceuticals
  • Medicinal Chemistry, Process Chemistry, Industrial Chemistry
  • Pharmaceutical Formulations, Solid forms, Treatment Regimes, Medical Uses
  • Patent Term Extensions (inc. SPCs) and Regulatory Exclusivity for Drug Products
  • Polymers and Composite Materials


    Andrew primarily works with large and small pharma companies. Recent areas of pharma support have included extensive patent drafting, prosecution, IP strategy, freedom to operate work as well as more specialist advice on the overall exclusivity picture for pharma assets as part of due diligence work. He also works with FMCG companies with both prosecution and opposition work.


    Prior to his IP career Andrew also spent 3 years working in pharmaceutical process chemistry and has more recently built experience in polymer science and in several FMCG technology areas. He has a first class Master’s degree in chemistry from the University of Oxford and a PhD in organic synthesis from the University of Bristol. Andrew is dual-qualified as both a UK and European Patent Attorney. He joined Mewburn Ellis in 2020.